Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 2
2020 5
2021 6
2022 7
2023 4
2024 6
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean torres cuesta a (3 results)?
Monkeypox: disease epidemiology, host immunity and clinical interventions.
Lum FM, Torres-Ruesta A, Tay MZ, Lin RTP, Lye DC, Rénia L, Ng LFP. Lum FM, et al. Among authors: torres ruesta a. Nat Rev Immunol. 2022 Oct;22(10):597-613. doi: 10.1038/s41577-022-00775-4. Epub 2022 Sep 5. Nat Rev Immunol. 2022. PMID: 36064780 Free PMC article. Review.
Variant-Specific IgA Protects Against Omicron Infection.
Goh YS, Fong SW, Hor PX, Loh CY, Wang B, Salleh SNM, Ngoh EZX, Lee RTC, Poh XY, Rao S, Chia PY, Ong SWX, Lee TH, Lim C, Teo J, Pada S, Sun LJ, Ong DLS, Somani J, Lee ES, Maurer-Stroh S, Wang CI, Leo YS, Lye DC, Young BE, Ng LFP, Renia L; NCID Study Group; COVID-19 Cohort Study Group. Goh YS, et al. J Infect Dis. 2024 Aug 16;230(2):e287-e291. doi: 10.1093/infdis/jiad525. J Infect Dis. 2024. PMID: 37996071 Free PMC article. Clinical Trial.
Crosstalk between CD64+MHCII+ macrophages and CD4+ T cells drives joint pathology during chikungunya.
Lum FM, Chan YH, Teo TH, Becht E, Amrun SN, Teng KW, Hartimath SV, Yeo NK, Yee WX, Ang N, Torres-Ruesta AM, Fong SW, Goggi JL, Newell EW, Renia L, Carissimo G, Ng LF. Lum FM, et al. Among authors: torres ruesta am. EMBO Mol Med. 2024 Mar;16(3):641-663. doi: 10.1038/s44321-024-00028-y. Epub 2024 Feb 8. EMBO Mol Med. 2024. PMID: 38332201 Free PMC article.
Relative deficiency in interferon-γ-secreting CD4+ T cells is strongly associated with poorer COVID-19 vaccination responses in older adults.
Ho VWT, Boon LH, Cui J, Juequn Z, Shunmuganathan B, Gupta R, Tan NYJ, Qian X, Purushotorman K; SCOPE Cohort Study Group; Fong SW, Renia L, Ng LFP, Angeli V, Chen J, Kennedy BK, Ong CWM, Macary PA. Ho VWT, et al. Aging Cell. 2024 Apr;23(4):e14099. doi: 10.1111/acel.14099. Epub 2024 Feb 5. Aging Cell. 2024. PMID: 38317404 Free PMC article.
Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial.
Poh XY, Torres-Ruesta A, Yoong T, Wong N, Tan CW, Rouers A, Chavatte JM, Goh YS, Rao S, Chia PY, Ong SWX, Lee TH, Sadarangani SP, Lin RJH, Neo V, Kam IKJ, Huang Y, Hor PX, Loh CY; PRIBIVAC study group; Yeoh AY, Lim DRX, Chia W, Ren EC, Lin RTP, Fong SW, Renia L, Lye DC, Wang LF, Ng LFP, Young BE. Poh XY, et al. Among authors: torres ruesta a. Vaccine. 2024 Nov 14;42(25):126275. doi: 10.1016/j.vaccine.2024.126275. Epub 2024 Sep 5. Vaccine. 2024. PMID: 39241318 Free article. Clinical Trial.
Heterologous mRNA vaccine boosters induce a stronger and longer-lasting antibody response against Omicron XBB variant.
Tay MZ, Goh YS, Fong SW, Chang ZW, Rouers A, Wong N, Torres-Ruesta A, Huang Y, Selvam SK, Hor PX, Loh CY, Wang B, Mohd Salleh SN, Ngoh EZX, Lee RTC, Neo V, Kam IKJ, Poh XY, Rao S, Chia PY, Ong SWX, Lee TH, Lim C, Teo J; NCID Study Group; PRIBIVAC Cohort Study Group; Maurer-Stroh S, Wang CI, Leo YS, Lin RTP, Lye DC, Young BE, Ng LFP, Renia L. Tay MZ, et al. Among authors: torres ruesta a. Lancet Reg Health West Pac. 2023 Apr;33:100732. doi: 10.1016/j.lanwpc.2023.100732. Epub 2023 Mar 7. Lancet Reg Health West Pac. 2023. PMID: 37125085 Free PMC article. No abstract available.
First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial.
Poh XY, Lee IR, Tan CW, Chavatte JM, Fong SW, Goh YS, Rouers A, Wong N, Torres-Ruesta A, Mah SYY, Yeoh AYY, Gandhi M, Rahman N, Chin YQ, Lim JJ, Yoong TJK, Rao S, Chia PY, Ong SWX, Lee TH, Sadarangani SP, Lin RJH, Lim DRX, Chia W, Renia L, Ren EC, Lin RTP, Lye DC, Wang LF, Ng LFP, Young BE. Poh XY, et al. Among authors: torres ruesta a. EBioMedicine. 2024 Sep;107:105275. doi: 10.1016/j.ebiom.2024.105275. Epub 2024 Aug 12. EBioMedicine. 2024. PMID: 39137572 Free PMC article. Clinical Trial.
27 results